License Agreement Sample Contracts

Elite Pharmaceuticals, Inc. – MANUFACTURING AND LICENSE AGREEMENT Between Elite Pharmaceuticals, Inc. And Epic Pharma LLC MANUFACTURING AND LICENSE AGREEMENT (October 17th, 2018)

This License Agreement ("Agreement") is entered into as of the 1st day of October, 2013 by and between EPIC PHARMA LLC, a Delaware limited liability company ("EPIC"), and ELITE PHARMACEUTICALS, INC., a Nevada corporation and ELITE LABORATORIES, INC. (a subsidiary of Elite Pharmaceuticals, Inc.), a Delaware corporation (collectively, "ELITE").

Axonics Modulation Technologies, Inc. – October 1, 2013 Axonics Modulation Technologies, Inc. 16411 Scientific Way Suite 200 Irvine, CA 92618 Dear Sirs: Reference Is Made to That Certain License Agreement of Even Date Herewith Between Axonics Modulation Technologies, Inc. And the Undersigned. This Will Confirm That at Your Option the Undersigned Will Expand the Territories Included Under the License to Be Worldwide Or, if You So Direct, the Undersigned Will Enter Into a Comparable License Agreement Covering Areas Outside the United States With an Entity Controlled by the Founders of Axonics Modulation Technologies, Inc. In the Latte (October 5th, 2018)
Axonics Modulation Technologies, Inc. – License Agreement (October 5th, 2018)
Tpt Global Tech, Inc. – PRODUCT, SOFTWARE & SERVICES LICENSE AGREEMENT Between New Orbit Technologies, S.A.P.I. De C.V. And TPT Global Tech, Inc. Dated April 17, 2017 (October 2nd, 2018)
StoneCo Ltd. – Contrato De Participacao Nos Arranjos De Pagamento Da Visa Do Brasil E Licenciamento De Marca Registrada Visa Payment Arrangements Participation and Trademark Blicense Agreement (October 1st, 2018)
Intellectual Property Cross-License Agreement (October 1st, 2018)

THIS INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this Agreement) is made as of October 1, 2018 (the Effective Date) by and between Fortive Corporation, a Delaware corporation (Fortive), Altra Industrial Motion Corp, a Delaware corporation (Altra), on behalf of itself and its Subsidiaries, including Stevens Holding Company, Inc., a Delaware corporation (Newco) and the Direct Sales Purchasers (as defined below). Altra and Fortive are collectively referred to herein as the Parties and each individually referred to herein as a Party. Capitalized terms used herein without being defined in this Agreement shall have the respective meanings given such terms in the Separation and Distribution Agreement, dated as of March 7, 2018 (as amended, modified or supplemented from time to time in accordance with its terms, the Distribution Agreement), by and between Fortive, Newco and Altra.

Arog Pharmaceuticals, Inc. – First Amendment to the January S, 2015, License Agreement Between AROG Pharmaceuticals, Inc. And Videra Pharmaceuticals, LLC (September 28th, 2018)

This Amendment ("Amendment"), dated June 22, 2018, (the "Amendment Effective Date") is made by and between AROG Pharmaceuticals, Inc., (hereinafter referred to as "Company"), with a place of business at 5420 LBJ Freeway, Ste. 410, Dallas, Texas 75240, United States, and Videra Pharmaceuticals, LLC (hereinafter referred to as "Licensee"), with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, United States. Company and Licensee are each individually referred to herein as a "Party" and collectively as the "Parties."

Arog Pharmaceuticals, Inc. – License Agreement (September 28th, 2018)

This License Agreement (the "Agreement") is entered into and made effective as of January 5, 2015 ("Effective Date") by and between Arog Pharmaceuticals Inc., a Delaware corporation having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 ("Company") and Videra Pharmaceuticals, LLC, a Delaware limited liability company having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 ("Licensee"). Licensee and Company are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Assignment of Trademarks and License Agreement (September 28th, 2018)

This Agreement is entered into as of the 2nd day of November, 1994, by and between BORG-WARNER SECURITY CORPORATION (formerly known as Borg-Warner Corporation), a Delaware corporation having a place of business at 200 South Michigan Avenue, Chicago, Illinois 60604 ("Security"), and BORG-WARNER AUTOMOTIVE, INC. (formerly a subsidiary of Borg-Warner Corporation), a Delaware corporation having a place of business at 200 South Michigan Avenue, Chicago, Illinois 60604 ("Automotive").

Amendment to Assignment of Trademarks and License Agreement (September 28th, 2018)

This Amendment to Assignment of Trademarks and License Agreement ("Amendment") is entered into as of the 31st day of July, 1998, by and between Borg-Warner Security Corporation ("BWSC") and Borg-Warner Automotive, Inc. ("BWA") (collectively referred to as the "Parties").

AMENDED AND RESTATED LICENSE AGREEMENT University of Michigan File [***] (September 26th, 2018)

This Amended and Restated License Agreement (the Agreement) is effective as of November 9, 2015 (the Effective Date), between Atterocor, Inc. (LICENSEE) having the address in Article 13 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (MICHIGAN). LICENSEE and MICHIGAN may be referred to herein individually as a Party, and collectively as the Parties.

License Agreement Between Aldeyra Therapeutics, Inc. And Madrigal Pharmaceuticals, Inc. (September 25th, 2018)
Smart Energy Solutions Inc – License Agreement With Yissum (September 24th, 2018)
Arog Pharmaceuticals, Inc. – License Agreement (September 24th, 2018)

THIS LICENSE AGREEMENT (the "Agreement") is made effective as of the 28th day of April, 2010 (the "Effective Date"), by and between AROG Pharmaceuticals LLC, a limited partnership organized and existing under the laws of the State of Texas, with offices at Four Forest Plaza, 12222 Merit Drive, Suite 820, Dallas, Texas 75251 ("LICENSEE"), PFIZER Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, New York 10017 ("PFIZER") (each of PFIZER and LICENSEE, a "Party" and collectively, the "Parties"), and solely for purposes of Sections 10.3.4, 10.3.5, 17.3 and 17.4, DAVA Oncology, LP, a limited partnership organized and existing under the laws of the State of Texas, with offices at Four Forest Plaza, 12222 Merit Drive, Suite 280, Dallas, Texas 75251 ("DAVA").

Arog Pharmaceuticals, Inc. – First Amendment to the January S, 2015, License Agreement Between AROG Pharmaceuticals, Inc. And Videra Pharmaceuticals, LLC (September 24th, 2018)

This Amendment ("Amendment"), dated June 22, 2018, (the "Amendment Effective Date") is made by and between AROG Pharmaceuticals, Inc., (hereinafter referred to as "Company"), with a place of business at 5420 LBJ Freeway, Ste. 410, Dallas, Texas 75240, United States, and Videra Pharmaceuticals, LLC (hereinafter referred to as "Licensee"), with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, United States. Company and Licensee are each individually referred to herein as a "Party" and collectively as the "Parties."

Arog Pharmaceuticals, Inc. – License Agreement (September 24th, 2018)

This License Agreement (the "Agreement") is entered into and made effective as of January 5, 2015 ("Effective Date") by and between Arog Pharmaceuticals Inc., a Delaware corporation having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 ("Company") and Videra Pharmaceuticals, LLC, a Delaware limited liability company having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 ("Licensee"). Licensee and Company are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

StoneCo Ltd. – Contrato De Participacao Nos Arranjos De Pagamento Da Visa Do Brasil E Licenciamento De Marca Registrada Visa Payment Arrangements Participation and Trademark Blicense Agreement (September 21st, 2018)
Osmotica Pharmaceuticals Ltd – This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission. License Agreement (September 14th, 2018)

THIS LICENSE AGREEMENT (Agreement) is made as of August 31, 2011 (the Effective Date) by and between VOOM, LLC, a limited liability company organized and existing under the laws of Delaware, having an office located at 625 Via Trepadora, Santa Barbara, CA 93110 (Licensor), and RevitaLid, Inc., a corporation organized and existing under the laws of Delaware, having a principal place of business at 400 N. Ashley Dr., Ste. 1950, Tampa, FL 33602 (RevitaLid). Licensor and RevitaLid are each individually referred to herein as a Party and collectively referred to as the Parties.

VistaGen Therapeutics, Inc. – License Agreement (September 13th, 2018)

This License Agreement ("Agreement"), effective on September 11, 2018, is by and between Pherin Pharmaceuticals, Inc., a California corporation with offices at 1014 Barbara Avenue, Mountain View, CA 94040 ("LICENSOR"), and VistaGen Therapeutics, Inc., a Nevada corporation with offices at 343 Allerton Avenue, South San Francisco, California 94080 ("LICENSEE").

Principia Biopharma Inc. – License Agreement (September 11th, 2018)
Centrexion Therapeutics Corp – License Agreement (September 10th, 2018)
Urovant Sciences Ltd. – License Agreement (September 10th, 2018)

THIS LICENSE AGREEMENT (this Agreement) is made and entered into this February 3, 2017 (the Effective Date), by and between Merck Sharp & Dohme Corp. a corporation organized and existing under the laws of the State of New Jersey (Merck), and Urovant Sciences GmbH (Urovant), a company organized and existing pursuant to the laws of Switzerland, [***]. Merck and Urovant are sometimes referred to herein individually as a Party and collectively as the Parties.

Aptorum Group Ltd – Addendum to License Agreement (September 5th, 2018)

This Addendum, effective as of 9 February 2018, is hereby made a part of the License Agreement entered into as of 3 July 2017 ("Agreement") between Aptorum Therapeutics Limited (formerly known as APTUS Therapeutics Limited), hereinafter "Aptorum" on the one part and

License Agreement (August 31st, 2018)

THIS LICENSE AGREEMENT (the "Agreement") is dated as of September 21, 2016 (the "Effective Date") by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation ("Ligand"), Neurogen Corporation, a Delaware corporation ("Neurogen") and CyDex Pharmaceuticals, Inc., a Delaware corporation ("CyDex"), and Seelos Therapeutics, Inc., a Delaware corporation ("Seelos"). It is understood that Neurogen and CyDex are wholly-owned subsidiaries of Ligand; that the technology being licensed hereunder toward Aplindore Licensed Products and H3 Receptor Licensed Products is owned or in-licensed by Neurogen (it being possible that some components of the Aplindore Program and/or the H3 Receptor Program are instead owned by Ligand) and that the technology being licensed hereunder toward CEA Licensed Products is owned or in-licensed by CyDex (it being possible that some components of the CEA Program are instead owned by Ligand). Ligand, Neurogen and CyDex are referred to collectively herein as "Li

Urovant Sciences Ltd. – [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 406 of the Securities Act of 1933, as Amended. License Agreement (August 30th, 2018)

THIS LICENSE AGREEMENT (the Agreement) is entered into as of August 24, 2018 (the Effective Date), by and between ION CHANNEL INNOVATIONS, LLC, a limited liability company organized under the laws of the State of New York and having an address of 23 Agnes Circle, Ardsley, NY 10502, U.S. (Licensor), and UROVANT SCIENCES, GMBH, a company organized under the laws of Switzerland and having an address of Viaduktstrasse 8, 4051 Basel, Switzerland (Licensee). Licensor and Licensee may be referred to herein individually as a Party or collectively as the Parties.

Smart Energy Solutions Inc – License Agreement With Yissum (August 30th, 2018)
Inmune Bio, Inc. – License Agreement (August 30th, 2018)

This LICENSE AGREEMENT (this "Agreement"), effective as of October 3, 2017 (the "Effective Date"), is made by and between INMUNE BIO INC., a Nevada corporation ("INmune"), having a principal place of business at 1224 Prospect Street, Suite 150, La Jolla, California 92037, and XENCOR, INC., a Delaware corporation ("Xencor"), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016, U.S.A. INmune and Xencor may each be referred to herein, individually, as a "Party" or, collectively, as the "Parties."

Sutro Biopharma Inc – License Agreement Dated as of September 16, 2014 by and Between Sutro Biopharma Inc. And Merck Kgaa (August 29th, 2018)

This License Agreement (this Agreement) is dated as of September 16, 2014 (the Effective Date) by and between Sutro Biopharma Inc., a corporation organized under the laws of California having a place of business at 310 Utah Avenue, Suite 150, South San Francisco, CA 94080, USA (Sutro), and Merck KGaA a corporation with general partners organized under German law having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany (Merck). Sutro and Merck may be referred to herein as a Party or, collectively, as Parties.

Axonics Modulation Technologies, Inc. – October 1, 2013 Axonics Modulation Technologies, Inc. 16411 Scientific Way Suite 200 Irvine, CA 92618 Dear Sirs: Reference Is Made to That Certain License Agreement of Even Date Herewith Between Axonics Modulation Technologies, Inc. And the Undersigned. This Will Confirm That at Your Option the Undersigned Will Expand the Territories Included Under the License to Be Worldwide Or, if You So Direct, the Undersigned Will Enter Into a Comparable License Agreement Covering Areas Outside the United States With an Entity Controlled by the Founders of Axonics Modulation Technologies, Inc. In the Latte (August 28th, 2018)
Axonics Modulation Technologies, Inc. – License Agreement (August 28th, 2018)
Y-mAbs Therapeutics, Inc. – LICENSE AGREEMENT for MSKs Technology CD33 Antibodies and Constructs Thereof Between MEMORIAL SLOAN KETTERING CANCER CENTER and Y-Mabs THERAPEUTICS, INC. Dated: November 10, 2017 (August 24th, 2018)

This Agreement (the Agreement) is effective on the date of the last signature below (Effective Date), and is by and between Memorial Sloan Kettering Cancer Center (MSK), a New York not-for-profit corporation with its principal office at 1275 York Avenue, New York, NY, and Y-mAbs Therapeutics, Inc., a Delaware corporation with its principal office at 750 3rd Avenue, New York, N.Y. 10017 (LICENSEE). MSK and LICENSEE are sometimes referred to singly as Party and collectively as Parties.

Y-mAbs Therapeutics, Inc. – LICENSE AGREEMENT for MSKs Technology [****] and [****] Antibodies and Multimerization Technology Between MEMORIAL SLOAN-KETTERING CANCER CENTER and Y-Mabs THERAPEUTICS, INC. (August 24th, 2018)

This Agreement (the Agreement) is effective on the date of the last signature below (Effective Date), and is by and between Memorial Sloan-Kettering Cancer Center (MSK), a New York not-for-profit corporation with its principal office at 1275 York Avenue, New York, NY, and Y-mAbs Therapeutics, Inc., a Delaware corporation with its principal office at c/o Satterlee Stephens Burke & Burke LLP. 230 Park Avenue, Suite 1130, New York, New York 10169 (LICENSE). MSK and LICENSEE are sometimes referred to singly as Party and collectively as Parties.

Tiziana Life Sciences plc – License Agreement (August 23rd, 2018)

This License Agreement ("Agreement") by and between Nerviano Medical Sciences, Viale Pasteur 10, Nerviano, Milano, Italy ( "Licensor" or "NMS"), and Tiziana Life Sciences Plc, 18 South Street, Mayfair, London W1K 1DG, United Kingdom ("Licensee" or "TIZIANA") is made effective as of the date that the Agreement is signed by the last Party to sign below ("Effective Date"). Licensor and Licensee are each hereafter referred to individually as a "Party" and together as the "Parties."

Gritstone Oncology, Inc. – Amendment Number One to License Agreement (August 23rd, 2018)

This Amendment Number One to License Agreement (Amendment No. 1) is made by and between (a) Gritstone Oncology, Inc., a Delaware corporation having a place of business at 5858 Horton Street, Suite 210, Emeryville, California 94608, U.S.A. (Gritstone), on the one hand, and (b) Protiva Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (Protiva), and Arbutus Biopharma Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (ABUS and together with Protiva, Arbutus), on the other hand. Gritstone, Protiva, and ABUS may each be referred to herein as a Party and collectively as the Parties.

Immunomedics, Inc. – License Agreement (August 23rd, 2018)

This License Agreement (the "Agreement") is effective as of April 4, 2018 (the "Effective Date"), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation ("TSRI"), and IMMUNOMEDICS, INC., a Delaware corporation ("Licensee"), each located at the respective address set forth in Section 13.15 below, with respect to the facts set forth below.